Jaguar Health is a commercial stage plant medicine prescription pharmaceutical company focused on developing and commercializing gastrointestinal products on a global basis. Co.'s wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used in rainforest areas. Co.'s Mytesi (crofelemer) product is approved by the U.S. Food and Drug Administration for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. In addition, a second-generation proprietary anti-secretory agent, lechlemer, is in development for cholera. The JAGX stock yearly return is shown above.
The yearly return on the JAGX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the JAGX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|